Skip to main content
Erschienen in: Surgical Endoscopy 3/2020

29.05.2019

Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry

verfasst von: Xavier Andújar, Carme Loras, Begoña González, Milena Socarras, Vicente Sanchiz, Maia Boscà, Eugeni Domenech, Margalida Calafat, Esther Rodríguez, Beatriz Sicilia, Xavier Calvet, Jesús Barrio, Jordi Guardiola, Eva Iglesias, María José Casanova, Yolanda Ber, David Monfort, Antonio López-Sanromán, Iago Rodríguez-Lago, Luís Bujanda, Lucía Márquez, María Dolores Martín-Arranz, Yamile Zabana, Fernando Fernández-Bañares, María Esteve, the ENEIDA registry of GETECCU

Erschienen in: Surgical Endoscopy | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

There is no information regarding the outcome of Crohn’s disease (CD) patients treated with endoscopic balloon dilation (EBD) in non-referral hospitals, nor on the efficacy of EBD in ulcerative colitis (UC). We report herein the results of the largest series published to date.

Aim

To assess the efficacy and safety of EBD for inflammatory bowel disease (IBD) stenosis performed in 19 hospitals with different levels of complexity and to determine factors related to therapeutic success.

Methods

We identified IBD patients undergoing EBD in the ENEIDA database. Efficacy of EBD was compared between CD and UC and between secondary and tertiary hospitals. Predictive factors of therapeutic success were assessed with multivariate analysis.

Results

Four-hundred dilations (41.2% anastomotic) were performed in 187 IBD patients (13 UC/Indeterminate colitis). Technical and therapeutic success per dilation was achieved in 79.5% and 55.3%, respectively. Therapeutic success per patient was achieved in 78.1% of cases (median follow-up: 40 months) with 49.7% requiring more than one dilation. No differences related to either diagnosis or hospital complexity was found. Technical success [OR 4.12 (95%CI 2.4–7.1)] and not receiving anti-TNF at the time of dilation [OR 1.7 (95% CI 1.1–2.6)] were independently related to therapeutic success per dilation. A stricture length ≤ 2 cm [HR 2.43 (95% CI 1.11–5.31)] was a predictive factor of long-term success per patient. The rate of major complications was 1.3%.

Conclusions

EBD can be performed with similar efficacy and safety in hospitals with differing levels of complexity and it might be a suitable treatment for UC with short stenosis. To achieve a technical success and the short length of the stenosis seem to be critical for long-term therapeutic success.
Literatur
1.
Zurück zum Zitat Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R et al (1996) Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 39(5):684–689CrossRef Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R et al (1996) Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 39(5):684–689CrossRef
2.
Zurück zum Zitat McKaig BC, Hughes K, Tighe PJ, Mahida YR (2002) Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 282(1):C172–C182CrossRef McKaig BC, Hughes K, Tighe PJ, Mahida YR (2002) Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 282(1):C172–C182CrossRef
3.
Zurück zum Zitat Rieder F, Lawrance IC, Leite A, Sans M (2011) Predictors of fibrostenotic Crohn’s disease. Inflamm Bowel Dis 17(9):2000–2007CrossRef Rieder F, Lawrance IC, Leite A, Sans M (2011) Predictors of fibrostenotic Crohn’s disease. Inflamm Bowel Dis 17(9):2000–2007CrossRef
4.
Zurück zum Zitat Pucilowska JB, Williams KL, Lund PK (2010) Fibrogenesis IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol 279(4):653–659 Pucilowska JB, Williams KL, Lund PK (2010) Fibrogenesis IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol 279(4):653–659
5.
Zurück zum Zitat Szabò H, Fiorino G, Spinelli A, Rovida S, Repici A, Malesci AC et al (2010) Review article: anti-fibrotic agents for the treatment of Crohn’s disease—lessons learnt from other diseases. Aliment Pharmacol Ther 31(2):189–201PubMed Szabò H, Fiorino G, Spinelli A, Rovida S, Repici A, Malesci AC et al (2010) Review article: anti-fibrotic agents for the treatment of Crohn’s disease—lessons learnt from other diseases. Aliment Pharmacol Ther 31(2):189–201PubMed
6.
Zurück zum Zitat Cosnes J, Gower-Rousseau C, Seksik P, Cortot A, Gower-Rousseau C, Seksik P et al (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140(6):1785–1794CrossRef Cosnes J, Gower-Rousseau C, Seksik P, Cortot A, Gower-Rousseau C, Seksik P et al (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140(6):1785–1794CrossRef
7.
Zurück zum Zitat Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J et al (2007) Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 5:1430–1438CrossRef Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J et al (2007) Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 5:1430–1438CrossRef
8.
Zurück zum Zitat Peyrin-Biroulet L, Loftus EV, Colombel J-F, Sandborn WJ (2010) The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 105(2):289–297CrossRef Peyrin-Biroulet L, Loftus EV, Colombel J-F, Sandborn WJ (2010) The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 105(2):289–297CrossRef
9.
Zurück zum Zitat Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99:956–963CrossRef Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99:956–963CrossRef
10.
Zurück zum Zitat Wibmer AG, Kroesen AJ, Gröne J, Buhr H-J, Ritz J-P (2010) Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease–review of the literature. Int J Colorectal Dis 25(10):1149–1157CrossRef Wibmer AG, Kroesen AJ, Gröne J, Buhr H-J, Ritz J-P (2010) Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease–review of the literature. Int J Colorectal Dis 25(10):1149–1157CrossRef
11.
Zurück zum Zitat Hassan C, Zullo A, DeFrancesco V, Ierardi E, Giustini M, Pitidis A et al (2007) Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther 26:1457–1464CrossRef Hassan C, Zullo A, DeFrancesco V, Ierardi E, Giustini M, Pitidis A et al (2007) Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther 26:1457–1464CrossRef
12.
Zurück zum Zitat Thienpont C, D’Hoore A, Vermeire S, Demedts I, Bisschops R, Coremans G et al (2010) Long-term outcome of endoscopic dilatation in patients with Crohn’s disease is not affected by disease activity or medical therapy. Gut 59(3):320–324CrossRef Thienpont C, D’Hoore A, Vermeire S, Demedts I, Bisschops R, Coremans G et al (2010) Long-term outcome of endoscopic dilatation in patients with Crohn’s disease is not affected by disease activity or medical therapy. Gut 59(3):320–324CrossRef
13.
Zurück zum Zitat Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C (2012) Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn’s disease. Aliment Pharmacol Ther 36(2):151–158CrossRef Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C (2012) Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn’s disease. Aliment Pharmacol Ther 36(2):151–158CrossRef
14.
Zurück zum Zitat Bhalme M, Sarkar S, Lal S, Bodger K, Baker R, Willert RP (2014) Endoscopic balloon dilatation of Crohn’s disease strictures: results from a large United kingdom series. Inflamm Bowel Dis 20(2):265–270CrossRef Bhalme M, Sarkar S, Lal S, Bodger K, Baker R, Willert RP (2014) Endoscopic balloon dilatation of Crohn’s disease strictures: results from a large United kingdom series. Inflamm Bowel Dis 20(2):265–270CrossRef
15.
Zurück zum Zitat Morar PS, Faiz O, Warusavitarne J, Brown S, Cohen R, Hind D et al (2015) Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn’s disease strictures. Aliment Pharmacol Ther 42(10):1137–1148CrossRef Morar PS, Faiz O, Warusavitarne J, Brown S, Cohen R, Hind D et al (2015) Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn’s disease strictures. Aliment Pharmacol Ther 42(10):1137–1148CrossRef
16.
Zurück zum Zitat Navaneethan U, Lourdusamy V, Njei B, Shen B (2016) Endoscopic balloon dilation in the management of strictures in Crohn???s disease: a systematic review and meta-analysis of non-randomized trials. Surg Endosc Other Interv Tech. 30(12):5434–5443CrossRef Navaneethan U, Lourdusamy V, Njei B, Shen B (2016) Endoscopic balloon dilation in the management of strictures in Crohn???s disease: a systematic review and meta-analysis of non-randomized trials. Surg Endosc Other Interv Tech. 30(12):5434–5443CrossRef
17.
Zurück zum Zitat Atreja A, Aggarwal A, Dwivedi S, Rieder F, Lopez R, Lashner BA et al (2014) Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn’s disease strictures. J Crohn’s Colitis. 8(5):392–400CrossRef Atreja A, Aggarwal A, Dwivedi S, Rieder F, Lopez R, Lashner BA et al (2014) Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn’s disease strictures. J Crohn’s Colitis. 8(5):392–400CrossRef
18.
Zurück zum Zitat Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC et al (2010) A lexicon for endoscopic adverse events: report of an ASGE workshop Gastrointest Endosc. Am Soc Gastrointest Endosc 71(3):446–454CrossRef Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC et al (2010) A lexicon for endoscopic adverse events: report of an ASGE workshop Gastrointest Endosc. Am Soc Gastrointest Endosc 71(3):446–454CrossRef
19.
Zurück zum Zitat Silverberg MS, Satsangi J, Ahmad T, Arnott IDR, Bernstein CN, Brant SR et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5A–36ACrossRef Silverberg MS, Satsangi J, Ahmad T, Arnott IDR, Bernstein CN, Brant SR et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5A–36ACrossRef
20.
Zurück zum Zitat Dear KLE, Hunter JO (2001) Colonoscopic hydrostatic balloon dilatation of Crohn’ s strictures. J Clin Gastroenterol 33(4):315–318CrossRef Dear KLE, Hunter JO (2001) Colonoscopic hydrostatic balloon dilatation of Crohn’ s strictures. J Clin Gastroenterol 33(4):315–318CrossRef
21.
Zurück zum Zitat Blomberg B, Rolny P, Järnerot G (1991) Endoscopic treatment of anastomotic strictures in Crohn’s disease. Endoscopy. 23(4):195–198CrossRef Blomberg B, Rolny P, Järnerot G (1991) Endoscopic treatment of anastomotic strictures in Crohn’s disease. Endoscopy. 23(4):195–198CrossRef
22.
Zurück zum Zitat Ferlitsch A, Reinisch W, Püpök A, Dejaco C, Schillinger M, Schöfl R et al (2006) Safety and efficacy of endoscopic balloon dilation for treatment of Crohn’s disease strictures. Endoscopy 38(5):483–487CrossRef Ferlitsch A, Reinisch W, Püpök A, Dejaco C, Schillinger M, Schöfl R et al (2006) Safety and efficacy of endoscopic balloon dilation for treatment of Crohn’s disease strictures. Endoscopy 38(5):483–487CrossRef
23.
Zurück zum Zitat Thomas-Gibson S, Brooker JC, Hayward CMM, Shah SG, Williams CB, Saunders BP (2003) Colonoscopic balloon dilation of Crohn’s strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol 15(5):485–488PubMed Thomas-Gibson S, Brooker JC, Hayward CMM, Shah SG, Williams CB, Saunders BP (2003) Colonoscopic balloon dilation of Crohn’s strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol 15(5):485–488PubMed
24.
Zurück zum Zitat Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE (2008) Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 134(3):680–687CrossRef Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE (2008) Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 134(3):680–687CrossRef
25.
Zurück zum Zitat Feldman M, Friedman LS, Brandt LJ (2016) Sleisenger and Fordtran’s gastrointestinal and liver disease, vol 2, 10th edn. Elsevier, Amsterdam, p 2616 Feldman M, Friedman LS, Brandt LJ (2016) Sleisenger and Fordtran’s gastrointestinal and liver disease, vol 2, 10th edn. Elsevier, Amsterdam, p 2616
26.
Zurück zum Zitat Sonnenberg A, Genta RM (2015) Epithelial Dysplasia and Cancer in IBD Strictures. J Crohns Colitis. 9(9):769–775CrossRef Sonnenberg A, Genta RM (2015) Epithelial Dysplasia and Cancer in IBD Strictures. J Crohns Colitis. 9(9):769–775CrossRef
27.
Zurück zum Zitat Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L, Amiot A, Altwegg R, Savoye G, Abitbol V, Bouguen G, Simon M, Duffas JP, Hébuterne X, Nancey S, Roblin X, Leteurtre E, Bommelaer G, Lefevre JH, Brunetti F, Guillon F, Bouhn P-BL (2015) Detection of dysplasia or cancer in 3.5% patients with inflammatory bowel disease and colonic strictures. Clin Gastroenterol Hepatol 13(10):1770–1775CrossRef Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L, Amiot A, Altwegg R, Savoye G, Abitbol V, Bouguen G, Simon M, Duffas JP, Hébuterne X, Nancey S, Roblin X, Leteurtre E, Bommelaer G, Lefevre JH, Brunetti F, Guillon F, Bouhn P-BL (2015) Detection of dysplasia or cancer in 3.5% patients with inflammatory bowel disease and colonic strictures. Clin Gastroenterol Hepatol 13(10):1770–1775CrossRef
28.
Zurück zum Zitat Khan F, Shen B (2019) Inflammation and neoplasia of the pouch in inflammatory bowel disease. Curr Gastroenterol Rep 21(4):1–7 Khan F, Shen B (2019) Inflammation and neoplasia of the pouch in inflammatory bowel disease. Curr Gastroenterol Rep 21(4):1–7
29.
Zurück zum Zitat Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G et al (2018) ECCO-ESCP consensus on surgery for Crohn’s disease. J Crohn’s Colitis 12(1):1–16 Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G et al (2018) ECCO-ESCP consensus on surgery for Crohn’s disease. J Crohn’s Colitis 12(1):1–16
30.
Zurück zum Zitat East JE, Brooker JC, Rutter MD, Saunders BP (2007) A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of crohn’s strictures. Clin Gastroenterol Hepatol 5(9):1065–1069CrossRef East JE, Brooker JC, Rutter MD, Saunders BP (2007) A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of crohn’s strictures. Clin Gastroenterol Hepatol 5(9):1065–1069CrossRef
31.
Zurück zum Zitat Loras C, Pérez-Roldan F, Gornals JB, Barrio J, Igea F, González-Huix F et al (2012) Endoscopic treatment with self-expanding metal stents for Crohn’s disease strictures. Aliment Pharmacol Ther 36(9):833–839CrossRef Loras C, Pérez-Roldan F, Gornals JB, Barrio J, Igea F, González-Huix F et al (2012) Endoscopic treatment with self-expanding metal stents for Crohn’s disease strictures. Aliment Pharmacol Ther 36(9):833–839CrossRef
Metadaten
Titel
Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry
verfasst von
Xavier Andújar
Carme Loras
Begoña González
Milena Socarras
Vicente Sanchiz
Maia Boscà
Eugeni Domenech
Margalida Calafat
Esther Rodríguez
Beatriz Sicilia
Xavier Calvet
Jesús Barrio
Jordi Guardiola
Eva Iglesias
María José Casanova
Yolanda Ber
David Monfort
Antonio López-Sanromán
Iago Rodríguez-Lago
Luís Bujanda
Lucía Márquez
María Dolores Martín-Arranz
Yamile Zabana
Fernando Fernández-Bañares
María Esteve
the ENEIDA registry of GETECCU
Publikationsdatum
29.05.2019
Verlag
Springer US
Erschienen in
Surgical Endoscopy / Ausgabe 3/2020
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-019-06858-z

Weitere Artikel der Ausgabe 3/2020

Surgical Endoscopy 3/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.